Caribou Biosciences, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

CRBU$0.41-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Common Stock · Additional Paid-InCapital · Accumulated Other Comprehensive (Loss) Income · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
BALANCE—December 31, 2025	95,143,690	$9	$718,578	$103	$(596,515)	$122,175
Issuances of common stock under ESPP	348,411	—	468	—	—	468
Issuances of common stock on exercise of options	6,200	—	9	—	—	9
Issuances of common stock in connection with ATM offering, net of offering expenses	1,078,768	1	2,219	—	—	2,220
Issuances of common stock upon vesting of RSUs	374,165	—	—	—	—	—
Stock-based compensation expense	—	—	2,357	—	—	2,357
Net loss	—	—	—	—	(25,085)	(25,085)
Other comprehensive loss	—	—	—	(126)	—	(126)
BALANCE—March 31, 2026	96,951,234	$10	$723,631	$(23)	$(621,600)	$102,018
Issuances of common stock on exercise of options	9,256	—	12	—	—	12
Issuances of common stock in connection with ATM offering, net of offering expenses	9,006,276	1	17,924	—	—	17,925
Issuances of common stock upon vesting of RSUs	28,887	—	—	—	—	—
Stock-based compensation expense	—	—	2,477	—	—	2,477
Net loss	—	—	—	—	(24,282)	(24,282)
Other comprehensive loss	—	—	—	(48)	—	(48)
BALANCE—June 30, 2026	105,995,653	$11	$744,044	$(71)	$(645,882)	$98,102
Issuances of common stock under ESPP	229,460	—	302	—	—	302
Issuances of common stock on exercise of options	6,750	—	10	—	—	10
Issuances of common stock in connection with ATM offering, net of offering expenses	1,480,869	—	2,677	—	—	2,677
Issuances of common stock upon vesting of RSUs	323,997	—	—	—	—	—
Stock-based compensation expense	—	—	2,163	—	—	2,163
Net loss	—	—	—	—	(26,612)	(26,612)
Other comprehensive loss	—	—	—	(9)	—	(9)
BALANCE—September 30, 2026	108,036,729	$11	$749,196	$(80)	$(672,494)	$76,633
BALANCE—December 31, 2024	92,378,577	$9	$701,077	$255	$(448,390)	$252,951
Issuances of common stock under ESPP	408,282	—	468	—	—	468
Issuances of common stock upon vesting of RSUs	217,743	—	—	—	—	—
Stock-based compensation expense	—	—	3,882	—	—	3,882
Net loss	—	—	—	—	(39,991)	(39,991)
Other comprehensive loss	—	—	—	(88)	—	(88)
BALANCE—March 31, 2025	93,004,602	$9	$705,427	$167	$(488,381)	$217,222
Issuances of common stock on exercise of options	15,000	—	6	—	—	6
Issuances of common stock upon vesting of RSUs	103,637	—	—	—	—	—
Stock-based compensation expense	—	—	3,129	—	—	3,129
Net loss	—	—	—	—	(54,098)	(54,098)
Other comprehensive loss	—	—	—	(127)	—	(127)
BALANCE—June 30, 2025	93,123,239	$9	$708,562	$40	$(542,479)	$166,132
Issuances of common stock under ESPP	229,114	—	277	—	—	277
Issuances of common stock upon vesting of RSUs	115,685	—	—	—	—	—
Stock-based compensation expense	—	—	2,931	—	—	2,931
Net loss	—	—	—	—	(27,548)	(27,548)
Other comprehensive income	—	—	—	53	—	53
BALANCE—September 30, 2025	93,468,038	$9	$711,770	$93	$(570,027)	$141,845

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.